No Data
No Data
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
FDA Accepts Astellas Pharma's Revised SNDA For IZERVAY In Geographic Atrophy Treatment
Astellas Pharma's Resubmission for IZERVAY Accepted by FDA
Human Embryonic Stem Cells Industry to Generate Revenues of $6.76 Billion by 2035, up From $2.26 Billion 2024 - Thermo Fisher Scientific, STEMCELL Technologies, and Astellas Pharma Dominate the Landscape
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Reported Earlier, China's NMPA Approves Astellas' VYLOY (Zolbetuximab) For Advanced Gastric Cancer Treatment
